Concepedia

Kay D. Rittenhouse

KD

17

Publications

872

Citations

15

H-Index

1998

Active since

Affiliations

Pfizer (United States)(Current)

University of North Carolina at Chapel Hill

University of Oxford

Regeneron (United States)

Bayer (United States)

Kay D. Rittenhouse is an author at Pfizer (United States) specializing in medicine, ophthalmology, and pharmacology.

ORCID

Top concepts

Publications per year

1998–2021

17

Publications

17

Ophthalmic Drug Delivery Systems for the Treatment of Retinal Diseases: Basic Research to Clinical Applications

Henry F. Edelhauser, Cheryl L. Rowe-Rendleman, Michael R. Robinson et al. · Investigative Ophthalmology & Visual Science · 2010 · 254 citations · Full text

Ocular Pharmacokinetics of Fluocinolone Acetonide After Retisert™ Intravitreal Implantation in Rabbits Over a 1-Year Period

Jean-Yves Driot, Gary D. Novack, Kay D. Rittenhouse et al. · Journal of Ocular Pharmacology and Therapeutics · 2004 · 99 citations

Immunomodulatory Effect of the Topical Ophthalmic Janus Kinase Inhibitor Tofacitinib (CP-690,550) in Patients with Dry Eye Disease

Jing-Feng Huang, Rolla Yafawi, Min Zhang et al. · Ophthalmology · 2012 · 74 citations · Full text

, , +9

Evaluations of Tear Protein Markers in Dry Eye Disease: Repeatability of Measurement and Correlation with Disease

Jing-Feng Huang, Yi Zhang, Kay D. Rittenhouse et al. · Investigative Ophthalmology & Visual Science · 2012 · 62 citations

Axitinib inhibits retinal and choroidal neovascularization in in vitro and in vivo models

Anand Giddabasappa, Kush Lalwani, Rand Norberg et al. · Experimental Eye Research · 2016 · 53 citations · Full text

, , +14

Rows per page

1–5 of 17